Insilico Medicine is moving its AI-discovered drug for idiopathic pulmonary fibrosis (IPF) into Phase III clinical trials. The drug, called rentosertib (formerly ISM001-055), is a first-in-class treatment designed using generative artificial intelligence. This marks a major step for AI-driven drug discovery, as the drug moves beyond early safety testing into late-stage efficacy trials.
What is Idiopathic Pulmonary Fibrosis and Why Rentosertib Matters
IPF is a serious lung disease that causes progressive scarring of lung tissue. This scarring, known as fibrosis, destroys the lungs' ability to transfer oxygen into the bloodstream. Patients diagnosed with IPF typically have a median survival of two to four years. There are currently no treatments that can reverse the disease.
Rentosertib works by inhibiting an enzyme called TNIK (Traf2- and NCK-interacting kinase). This target was discovered using Insilico Medicine's generative AI platform. The drug is taken orally and aims to address the underlying mechanisms that drive lung scarring.
Phase IIa Trial Results Show Promise
The Phase IIa trial was a randomized, double-blind, placebo-controlled study. It enrolled 71 patients across 22 clinical sites in China. Patients were split into groups receiving either rentosertib or a placebo for 12 weeks.
According to the results published in Nature Medicine, the trial showed that rentosertib was safe and well-tolerated. More importantly, it demonstrated a dose-dependent improvement in lung function, measured by forced vital capacity (FVC). This is a key measure of how well the lungs can work.
Insilico Medicine reported positive Phase IIa results in a press release, stating that the drug showed a "favorable safety profile" and "encouraging efficacy signals." The company noted that the results support moving forward into Phase III trials.
What Phase III Trials Will Test
Phase III trials are the final stage of human testing before a drug can be submitted for regulatory approval. These trials involve a much larger number of patients and are designed to confirm the drug's effectiveness, monitor side effects, and compare it to standard treatments.
For rentosertib, the Phase III trials will likely focus on confirming whether the drug can slow or stop the decline in lung function in IPF patients over a longer period. The positive Phase IIa data provides a strong foundation for this next step.
Our Take: A Milestone for AI in Drug Discovery
This is a significant moment for the field of AI-driven drug discovery. For years, the promise of AI in finding new drugs has been met with skepticism. Many AI-discovered drugs have failed to move past early-stage trials. Rentosertib's advancement to Phase III provides real-world evidence that AI can identify viable drug candidates.
However, Phase III trials are the hardest hurdle. Many drugs that show promise in Phase II fail in larger, longer studies. The real test for rentosertib — and for AI drug discovery as a whole — will come when these late-stage results are in. If successful, rentosertib could become one of the first AI-discovered drugs to reach patients, offering new hope for those suffering from IPF.
